Abstract 518P
Background
Artificial Intelligence (AI) holds the promise to transform medicine during diagnosis, management and therapy of diseases. The AICCELERATE project will introduce an operational approach to develop AI-enabled digital solutions to improve medical processes by creating a digital twin. In our study, we performed the first pilot application of the AICCELERATE project at Bambino Gesù Children’s Hospital in Rome (OPBG). The aim of our study is to design a supervised machine learning (ML) model to predict time to surgery and time to diagnosis based (outputs) on time from admission to first consultation and imaging (inputs) in newly diagnosed pediatric patients.
Methods
We included pediatric patients with new diagnoses of brain tumors, treated in OPBG from December 2017 to December 2022. We collected from EHR the following data: age and sex, start and end date of the first admission, department of hospitalization, consultations and radiological imaging date, diagnosis, and surgery date.
Results
We included 48 patients with a pediatric brain tumor, with a mean age of 8.6 years. We used a multiple linear regression model, which does not require large datasets such as more complex models. Our analysis showed that delayed consulting and imaging led to a delayed diagnosis, with the consulting presenting a higher importance than the imaging. This result was validated by the model’s estimated regressors coefficients, with the consulting factor being assigned a larger weight β_C=1.81 than the imaging factor β_I=-0.33. Similarly, we observed that delayed consulting and imaging led to a delayed surgery, estimating a higher coefficient for the consulting β_C=0.71 than the one estimated for the imaging β_I=-0.06. While the ML model achieved a reasonable performance in both frameworks, the time to surgery was predicted with a lower MAE 4.45±0.87 compared to the diagnosis MAE of 6.74±0.95.
Conclusions
This preliminary study conducted in a small number of patients, suggests that decreasing time to consultation can shorten time to surgery in children with brain cancer. As the AICCELERATE is ongoing, more accurate models will be developed and will help to better understand how to optimize the journey of children with brain cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
601P - Short-course radiotherapy based total neoadjuvant therapy combined with PD-1 inhibitor for locally advanced rectal cancer: Preliminary findings of TORCH
Presenter: Yaqi Wang
Session: Poster session 10
602P - Brazil-TNT: A randomized phase II trial of neo-adjuvant chemoradiation followed by FOLFIRINOX vs chemoradiation for stage II/III rectal cancer
Presenter: Diogo Bugano Diniz Gomes
Session: Poster session 10
604P - Overall and progression-free survival of patients with metastatic colorectal cancer: A real-world prospective, longitudinal cohort study on the continuum of care (PROMETCO)
Presenter: Miriam Koopman
Session: Poster session 10
605P - First-line chemotherapy with or without targeted therapies in metastatic colorectal cancer: The GEMCAD 14-01 prospective cohort
Presenter: HELENA OLIVERES
Session: Poster session 10
606P - Regional lymph nodes (N+ vs N0) in metastatic colorectal cancer
Presenter: Emerik Osterlund
Session: Poster session 10
608P - Resectability of colorectal liver metastases (CLM) with aflibercept plus FOLFIRI: Results from a prospective French cohort
Presenter: René Adam
Session: Poster session 10
609P - The impact of surgical invasiveness on the efficacy of mFOLFOX6 in resected colorectal liver metastasis: An exploratory analysis of JCOG0603
Presenter: Yasuyuki Takamizawa
Session: Poster session 10
610P - Predicting benefit from FOLFOXIRI plus bevacizumab versus FOLFOX/FOLFIRI plus bevacizumab in patients with metastatic colorectal cancer
Presenter: Marinde Bond
Session: Poster session 10
611P - SHR-1701 in combination with BP102 and XELOX as first-line (1L) treatment for patients (pts) with unresectable metastatic colorectal cancer (mCRC): Data from a phase II/III study
Presenter: Rui-Hua Xu
Session: Poster session 10